Comparative Pharmacology
Head-to-head clinical analysis: CEREBYX versus XCOPRI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEREBYX versus XCOPRI.
CEREBYX vs XCOPRI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fosphenytoin is a prodrug of phenytoin, which stabilizes neuronal membranes by blocking voltage-gated sodium channels, thereby inhibiting repetitive firing of action potentials.
XCOPRI (cenobamate) is a tetrazole derivative anticonvulsant that reduces neuronal excitability through inhibition of voltage-gated sodium channels (persistent sodium current) and positive allosteric modulation of GABA-A receptors.
Loading dose: 15-20 mg PE/kg IV/IM (max 1500 mg PE); maintenance: 4-6 mg PE/kg/day IV/IM divided q12h or q8h. Switch to oral phenytoin at equivalent dose.
Oral, 100 mg once daily for 2 weeks, then increase to 200 mg once daily. Maximum dose 400 mg once daily.
None Documented
None Documented
The terminal elimination half-life of fosphenytoin (converted to phenytoin) is approximately 15 hours (range 10-20 hours) in adults with normal hepatic function; after conversion, phenytoin half-life is dose-dependent and averages 22 hours (range 7-42 hours) at therapeutic concentrations.
50-70 hours, allowing once-daily dosing. Steady-state is reached in approximately 2 weeks.
Renal excretion of unchanged drug and metabolites accounts for approximately 80% of the dose; about 20% is eliminated in feces via biliary excretion.
Primarily renal, with approximately 70% of the dose excreted as unchanged drug in urine and 30% as inactive metabolites. Fecal elimination accounts for <2%.
Category C
Category C
Anticonvulsant
Anticonvulsant